Clinical Trials Overview
Since early approval of the ThinPrep® Pap Test in 1996, more than 170 studies evaluating it in a variety of clinical settings have been published in the peer-reviewed literature. Results of these studies demonstrate a wide range of benefits of this technology: increased disease detection, reduction of equivocal diagnoses, improved specimen adequacy, adjunctive molecular testing, morphology assessment and, last but not least, cost-effectiveness.

To date there have been more than 30 studies published in peer-reviewed journals, reporting on nearly 400,000 patients that show a significant increase in the detection of both low grade and high grade lesions using the ThinPrep Pap Test compared to the conventional Pap smear. The studies, conducted in seven different countries on four continents, also consistently demonstrate improved specimen adequacy.